Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs ... Development of antidrug antibodies are common with the LA GLP1-RAs (except for dulaglutide), but there is little ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs ...

Skye said that no neuropsychiatric adverse events were observed in Phase 1 data for its monoclonal antibody nimacimab ... with topline data in Q4 2025. The GLP-1R agonist drug being assessed ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist ... and on par with antibody conjugated NuSH analogs.” As for safety, gastrointestinal adverse events ...

In the SAPPHIRE trial, Scholar Rock tested apitegromab in patients aged two to 12 who were already being treated with the ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the ...

Scholar Rock’s stock price increased by 362% after the company announced data from the Phase III SAPPHIRE trial of ...